Oria Bioscience
Founded 2024 · 21 employees on LinkedIn · 1 known investors
Ori Biotech develops LYSO-Prep, a tool for organellar electrophysiology that enables high-throughput measurement of lysosomal ion channels such as TRPML1 using automated patch clamp and solid-supported membrane-based electrophysiology platforms. The product targets researchers characterizing lysosomal ion channel function in life sciences.
Investors · 1
In the news
Frequently asked questions
- What does Oria Bioscience do?
- Ori Biotech develops LYSO-Prep, a tool for organellar electrophysiology that enables high-throughput measurement of lysosomal ion channels such as TRPML1 using automated patch clamp and solid-supported membrane-based electrophysiology platforms. The product targets researchers characterizing lysosomal ion channel function in life sciences.
- Who are Oria Bioscience's investors?
- Oria Bioscience's investors include Newfund Capital.